Drug Trial Radar · NCT03078738
Safety and Pharmacokinetic Study of OMT-28 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Sep 28, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
75
Actual
Start
Feb 8, 2017
Primary completion
Mar 12, 2018
Study completion Mar 12, 2018
Sponsor
- Lead sponsor
- Omeicos Therapeutics GmbHIndustry
- Sponsor type
- Industry
- First posted
- Mar 13, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of this first-in-human study is to assess the safety, tolerability, PK and exploratory pharmacodynamics (PD) of single and multiple oral ascending doses of OMT-28 in healthy male subjects to support further clinical development of OMT-28 in the indication of atrial fibrillation (AF) and to obtain data on food and gender effects of OMT-28 to guide dosing for Phase II trials.
Conditions
- Healthy Volunteers
Interventions
OMT-28Drug
OMT-28 is a fully synthetic small molecule that belongs to the family of 17,18-epoxyeicosatetraenoic acids (17,18-EEQ) analogs, a natural metabolite of the omega-3 fatty acid eicosapentaenoic acid (EPA).
Matching PlaceboOther
Microcrystalline cellulose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety assessed by frequency and nature of treatment-emergent adverse eventsTime frame: From Day 1 to Day 21
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CRS-Mönchengladbach
Mönchengladbach, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.